Neuronal nicotinic receptors as analgesic targets: It's a winding road

Biochemical Pharmacology

Volumn 86, Issue 8, 2013, Pages 1208-1214

  Umana, Iboro C ^a   Daniele, Claire A ^a   McGehee, Daniel S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Analgesia; Nicotinic; Nociception; Pain

Indexed keywords

EID: 84885640206     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.08.001     Document Type: Review

References (93)

1. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clinical Journal of Pain 2008;24:469-78.
2. Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of longterm opioid therapy: a practitioner's guide. Primary Care Companion for CNS Disorders 2012;14.
3. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug and Alcohol Dependence 2003;69:215-32. (Pubitemid 36293934)
4. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug and Alcohol Dependence 2006;81:103-8.
5. Corti C. A history of smoking. Trans: Kessinger Publishing; 2007.
6. Davis L, Pollock LJ, Stone T. Visceral pain. Surgery Gynecology and Obstetrics 1932;55:418-27.
7. Hamann SR, Martin WR. Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem. Journal of Pharmacology and Experimental Therapeutics 1992;261:707-15.
8. Sahley TL, Berntson GG. Antinociceptive effects of central and systemic administrations of nicotine in the rat. Psychopharmacology 1979;65:279-83. (Pubitemid 10194755)
9. Fertig JB, Pomerleau OF, Sanders B. Nicotine-produced antinociception in minimally deprived smokers and ex-smokers. Addictive Behaviors 1986;11:239-48. (Pubitemid 16058028)
10. Henningfield JE, Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. Journal of Pharmacology and Experimental Therapeutics 1985;234:1-12. (Pubitemid 15034883)
11. Kottke TE, Brekke ML, Solberg LI, Hughes JR. A randomized trial to increase smoking intervention by physicians. Doctors helping smokers, Round I. JAMA 1989;261:2101-6. (Pubitemid 19097972)
12. Cepeda-Benito A, Reynoso J, McDaniel EH. Associative tolerance to nicotine analgesia in the rat: tail-flick and hot-plate tests. Experimental and Clinical Psychopharmacology 1998;6:248-54. (Pubitemid 28393942)
13. Garraffo HMS, Thomas F, Williams Michael. Epibatidine: from frog alkaloid to analgesic clinical candidates. A Testimonial to true grit! Heterocycles 2009;79:207-17.
14. Daly JW, Garraffo HM, Spande TF, Decker MW, Sullivan JP, Williams M. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. Natural Products Reports 2000;17:131-5. (Pubitemid 30218016)
15. Spande TF, Garraffo HM, Edwards MW, Yeh HJ, Pannell L, Daly JW. Epibatidine: a novel (chloropyridyl) azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. Journal of the American Chemical Society 1992;114:3475-8.
16. Sullivan JP, Decker MW, Brioni JD, Donnelly-Roberts D, Anderson DJ, Bannon AW, et al. (+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics 1994;271:624-31. (Pubitemid 24377744)
17. Rupniak NM, Patel S, Marwood R, Webb J, Traynor JR, Elliott J, et al. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. British Journal of Pharmacology 1994;113: 1487-93. (Pubitemid 24364438)
18. Sullivan J, Briggs C, Donnelly-Roberts D, Brioni J, Radek R, McKenna D, et al. (+/-)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Medicinal Chemistry Research 1994;4:502-16.
19. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998;279:77-81. (Pubitemid 28079158)
20. Lynch JJ3rd, Wade CL, Mikusa JP, Decker MW, Honore P. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model. European Journal of Pharmacology 2005;509:43-8. (Pubitemid 40248784)
21. Kesingland AC, Gentry CT, Panesar MS, Bowes MA, Vernier JM, Cube R, et al. Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pain 2000;86:113-8. (Pubitemid 30211710)
22. Holladay MW, Wasicak JT, Lin NH, He Y, Ryther KB, Bannon AW, et al. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. Journal of Medicinal Chemistry 1998;41:407-12. (Pubitemid 28093076)
23. Rowbotham MC, Duan WR, Thomas J, Nothaft W, Backonja MM. A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 2009;146:245-52.
24. Ueda M, Iida Y, Tominaga A, Yoneyama T, Ogawa M, Magata Y, et al. Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects. British Journal of Pharmacology 2010;159:1201-10.
25. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A, et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999;398:805-10.
26. Ramirez-Latorre J, Yu CR, Qu X, Perin F, Karlin A, Role L. Functional contributions of a5 subunit to neuronal acetylcholine receptor channels. Nature 1996;380:347-51.
27. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, et al. Assembly of human neuronal nicotinic receptor a5 subunits with a3, b2, and b4 subunits. Journal of Biological Chemistry 1996;271:17656-65.
28. Gerzanich V, Wang F, Kuryatov A, Lindstrom J. a5 Subunit alters desensitization, pharmacology, Ca2+ permeability and Ca2+ modulation of human neuronal a3 nicotinic receptors. Journal of Pharmacology and Experimental Therapeutics 1998;286:311-20. (Pubitemid 28318005)
29. Jackson KJ, Marks MJ, Vann RE, Chen X, Gamage TF, Warner JA, et al. Role of alpha5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. Journal of Pharmacology and Experimental Therapeutics 2010;334:137-46.
30. Jackson KJ, Sanjakdar SS, Muldoon PP, McIntosh JM, The Damaj MI. a3b4.*nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the a5 subunit in the mouse. Neuropharmacology 2013;70:228-35.
31. Damaj MI, Fei-Yin M, Dukat M, Glassco W, Glennon RA, Martin BR. Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. Journal of Pharmacology and Experimental Therapeutics 1998;284:1058-65. (Pubitemid 28130835)
32. Freitas K, Negus SS, Carroll FI, Damaj MI. In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model. British Journal of Pharmacology 2013;169:567-79.
33. Wang Y, Su DM, Wang RH, Liu Y, Wang H. Antinociceptive effects of choline against acute and inflammatory pain. Neuroscience 2005;132:49-56. (Pubitemid 40380713)
34. Bagdas D, Sonat FA, Hamurtekin E, Sonal S, Gurun MS. The antihyperalgesic effect of cytidine-50-diphosphate-choline in neuropathic and inflammatory pain models. Behavioural Pharmacology 2011;22:589-98.
35. Hamurtekin E, Gurun MS. The antinociceptive effects of centrally administered CDP-choline on acute pain models in rats: the involvement of cholinergic system. Brain Research 2006;1117:92-100. (Pubitemid 44573100)
36. Gao B, Hierl M, Clarkin K, Juan T, Nguyen H, Valk M, et al. Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain. Pain 2010;149:33-49.
37. Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective α7 nicotinic receptor partial agonist. Bioorganic and Medicinal Chemistry Letters 2001;11:319-21. (Pubitemid 32115836)
38. Broad LM, Felthouse C, Zwart R, McPhie GI, Pearson KH, Craig PJ, et al. PSAB-OFP, a selective α7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. European Journal of Pharmacology 2002;452:137-44. (Pubitemid 35291059)
39. Oatway MA, Chen Y, Weaver LC. The 5-HT3 receptor facilitates atlevel mechanical allodynia following spinal cord injury. Pain 2004;110:259-68. (Pubitemid 38953291)
40. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH. Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nature Neuroscience 2002;5:1319-26. (Pubitemid 35417767)
41. Farber L, Stratz T, Bruckle W, Spath M, Pongratz D, Lautenschlager J, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia-A highly selective and competitive 5-HT3 receptor antagonist. Scandinavian Journal of Rheumatology 2000;113(Suppl.):49-54.
42. Cordero-Erausquin M, Changeux JP. Tonic nicotinic modulation of serotoninergic transmission in the spinal cord. Proceedings of the National Academy of Sciences of the United States of America 2001;98:2803-7. (Pubitemid 32209564)
43. Furst S. Transmitters involved in antinociception in the spinal cord. Brain Research Bulletin 1999;48:129-41. (Pubitemid 29177388)
44. Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochemical Pharmacology 2007;74:1155-63. (Pubitemid 47417931)
45. Freitas K, Ghosh S. Ivy Carroll F, Lichtman AH, Imad Damaj M. Effects of alpha 7 positive allosteric modulators in murine inflammatory and chronic neuropathic pain models. Neuropharmacology 2013;65:156-64.
46. Nirogi R, Jabaris SL, Jayarajan P, Abraham R, Shanmuganathan D, Rasheed MA, et al. Antinociceptive activity of a4b2.*neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. European Journal of Pharmacology 2011;668:155-62.
47. Ji J, Bunnelle WH, Anderson DJ, Faltynek C, Dyhring T, Ahring PK, et al. A-366833: a novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane a4b2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models. Biochem. Pharmacology 2007;74:1253-62. (Pubitemid 47417939)
48. Lee CH, Zhu C, Malysz J, Campbell T, Shaughnessy T, Honore P, et al. a4b2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of a4b2 nAChR agonists in pain. Biochemical Pharmacology 2011;82:959-66.
49. Grupe M, Jensen AA, Ahring PK, Christensen JK, Grunnet M. Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (alpha4)3(-beta2)2 nicotinic ACh receptors. British Journal of Pharmacology 2013;168:2000-10.
50. Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, et al. Potentiation of analgesic efficacy but not side effects: co-administration of an alpha4beta2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochemical Pharmacology 2011;82:967-76.
51. Dube GR, Kohlhaas KL, Rueter LE, Surowy CS, Meyer MD, Briggs CA. Loss of functional neuronal nicotinic receptors in dorsal root ganglion neurons in a rat model of neuropathic pain. Neuroscience Letters 2005;376:29-34. (Pubitemid 40202932)
52. Genzen JR, Van Cleve W, McGehee DS. Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. Journal of Neurophysiology 2001;86:1773-82. (Pubitemid 32953226)
53. Genzen JR, McGehee DS. Short-and long-term enhancement of excitatory transmission in the spinal cord dorsal horn by nicotinic acetylcholine receptors. Proceedings of the National Academy of Sciences of the United States of America 2003;100:6807-12. (Pubitemid 36666661)
54. Rau KK, Johnson RD, Cooper BY. Nicotinic AChR in subclassified capsaicinsensitive and -insensitive nociceptors of the rat DRG. Journal of Neurophysiology 2005;93:1358-71. (Pubitemid 40283725)
55. Lang PM, Burgstahler R, Sippel W, Irnich D, Schlotter-Weigel B, Grafe P. Characterization of neuronal nicotinic acetylcholine receptors in the membrane of unmyelinated human C-fiber axons by in vitro studies. Journal of Neurophysiology 2003;90:3295-303. (Pubitemid 37430024)
56. Freysoldt A, Fleckenstein J, Lang PM, Irnich D, Grafe P, Carr RW. Low concentrations of amitriptyline inhibit nicotinic receptors in unmyelinated axons of human peripheral nerve. British Journal of Pharmacology 2009;158:797-805.
57. Vincler MA, Eisenach JC. Knock down of thea5 nicotinic acetylcholine receptor in spinal nerve-ligated rats alleviates mechanical allodynia. Pharmacology Biochemistry and Behavior 2005;80:135-43. (Pubitemid 40126211)
58. Rueter LE, Kohlhaas KL, Curzon P, Surowy CS, Meyer MD. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain 2003;103:269-76. (Pubitemid 36638816)
59. Gurun MS, Parker R, Eisenach JC, Vincler M. The effect of peripherally administered CDP-choline in an acute inflammatory pain model: the role of α7 nicotinic acetylcholine receptor. Anesthesia and Analgesia 2009;108:1680-7.
60. Gahring LC, Osborne AV, Reed M, Rogers SW. Neuronal nicotinic alpha7 receptors modulate early neutrophil infiltration to sites of skin inflammation. Journal of Neuroinflammation 2010;7:38.
61. Osborne-Hereford AV, Rogers SW, Gahring LC. Neuronal nicotinic alpha7 receptors modulate inflammatory cytokine production in the skin following ultraviolet radiation. Journal of Neuroimmunology 2008;193:130-9.
62. Rowley TJ, McKinstry A, Greenidge E, Smith W, Flood P. Antinociceptive and anti-inflammatory effects of choline in a mouse model of postoperative pain. British Journal of Anaesthesia 2010;105:201-7.
63. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003;421:384-8. (Pubitemid 36157937)
64. Gahring LC, Rogers SW. Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS Journals 2005;7:E885-94.
65. Lips KS, Pfeil U, KummerW. Coexpression of a9 and a10 nicotinic acetylcholine receptors in rat dorsal root ganglion neurons. Neuroscience 2002;115:1-5. (Pubitemid 35232683)
66. Peng H, Ferris RL, Matthews T, Hiel H, Lopez-Albaitero A, Lustig LR. Characterization of the human nicotinic acetylcholine receptor subunit alpha (a) 9 (CHRNA9) and alpha (a) 10 (CHRNA10) in lymphocytes. Life Sciences 2004;76:263-80. (Pubitemid 39452910)
67. Callaghan B, Haythornthwaite A, Berecki G, Clark RJ, Craik DJ, Analgesic Adams DJ. a-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. J. Neuroscience 2008;28:10943-51.
68. Azam L, McIntosh JM. Molecular basis for the differential sensitivity of rat and human a9a10 nAChRs to a-conotoxin RgIA. Journal of Neurochemistry 2012;122:1137-44.
69. Vincler M, Wittenauer S, Parker R, Ellison M, Olivera BM, McIntosh JM. Molecular mechanism for analgesia involving specific antagonism of a9a10 nicotinic acetylcholine receptors. Proceedings of the National Academy of Sciences of the United States of America 2006;103:17880-84. (Pubitemid 44852254)
70. Jurna I, Krauss P, Baldauf J. Depression by nicotine of pain-related nociceptive activity inthe rat thalamus and spinal cord. Clinical Investigator1993;72:65-73. (Pubitemid 24002254)
71. Hama AT, Lloyd GK, Menzaghi F. The antinociceptive effect of intrathecal administration of epibatidine with clonidine or neostigmine in the formalin test in rats. Pain 2001;91:131-8. (Pubitemid 32279618)
72. Rogers DT, Iwamoto ET. Multiple spinal mediators in parenteral nicotineinduced antinociception. Journal of Pharmacology and Experimental Therapeutics 1993;267:341-9. (Pubitemid 23325026)
73. Khan IM, Buerkle H, Taylor P, Yaksh TL. Nociceptive and antinociceptive responses to intrathecally administered nicotinic agonists. Neuropharmacology 1998;37:1515-25. (Pubitemid 28550425)
74. Rashid MH, Ueda H. Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Research 2002;953:53-62. (Pubitemid 35217807)
75. Cordero-Erausquin M, Pons S, Faure P, Changeux JP. Nicotine differentially activates inhibitory and excitatory neurons in the dorsal spinal cord. Pain 2004;109:308-18.
76. Damaj MI, Meyer EM, Martin BR. The antinociceptive effects α7 nicotinic agonists in an acute pain model. Neuropharmacology 2000;39:2785-91.
77. Abdrakhmanova GR, AlSharari S, Kang M, Damaj MI, Akbarali HI. a7-nAChRmediated suppression of hyperexcitability of colonic dorsal root ganglia neurons in experimental colitis. American Journal of Physiology Gastrointestinal and Liver Physiology 2010;299:G761-8.
78. Genzen JR, McGehee DS. Nicotinic modulation of GABAergic synaptic transmission in the spinal cord dorsal horn. Brain Research 2005;1031:229-37. (Pubitemid 40093075)
79. Kiyosawa A, Katsurabayashi S, Akaike N, Pang ZP, Akaike N. Nicotine facilitates glycine release in the rat spinal dorsal horn. Journal of Physiology 2001;536:101-10. (Pubitemid 32952221)
80. Rashid MH, Furue H, Yoshimura M, Ueda H. Tonic inhibitory role of a4b2 subtype of nicotinic acetylcholine receptors on nociceptive transmission in the spinal cord in mice. Pain 2006;125:125-35. (Pubitemid 44498970)
81. Yalcin I, Charlet A, Cordero-Erausquin M, Tessier LH, Picciotto MR, Schlichter R, et al. Nociceptive thresholds are controlled through spinal b2-subunit-containing nicotinic acetylcholine receptors. Pain 2011;152:2131-7.
82. Takeda D, Nakatsuka T, Papke R, Gu JG. Modulation of inhibitory synaptic activity by a non-a4b2, non-a7 subtype of nicotinic receptors in the substantia gelatinosa of adult rat spinal cord. Pain 2003;101:13-23. (Pubitemid 36044650)
83. Bitner RS, Nikkel AL, Curzon P, Arneric SP, Bannon AW, Decker MW. Role of the nucleus raphe magnus in antinociception produced by ABT-594: immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. Journal of Neuroscience 1998;18:5426-32. (Pubitemid 28311958)
84. Cucchiaro G, Commons KG. a4 nicotinic acetylcholine receptor subunit links cholinergic to brainstem monoaminergic neurotransmission. Synapse 2003;49:195-205. (Pubitemid 36870557)
85. Matsumoto M, Xie W, Inoue M, Ueda H. Evidence for the tonic inhibition of spinal pain by nicotinic cholinergic transmission through primary afferents. Molecular Pain 2007;3:41.
86. Dehkordi O, Millis RM, Dennis GC, Jazini E, Williams C, Hussain D, et al. Expression of alpha-7 and alpha-4 nicotinic acetylcholine receptors by GABAergic neurons of rostral ventral medulla and caudal pons. Brain Research 2007;1185:95-102. (Pubitemid 350166304)
87. Godinez-Chaparro B, Lopez-Santillan FJ, Orduna P, Granados-Soto V. Secondary mechanical allodynia and hyperalgesia depend on descending facilitation mediated by spinal 5-HT(4), 5-HT(6) and 5-HT(7) receptors. Neuroscience 2012;222:379-91.
88. Porreca F, Burgess SE, Gardell LR, Vanderah TW,Malan Jr. TP, Ossipov MH, et al. Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. Journal of Neuroscience 2001;21:5281-8.
89. Hamurtekin E, Bagdas D, Gurun MS. Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats. Neuroscience Letters 2007;420:116-21. (Pubitemid 46818674)
90. Baddick CG, Marks MJ. An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants. Biochemical Pharmacology 2011;82:828-41.
91. Guimaraes AP, Prado WA. Antinociceptive effects of carbachol microinjected into different portions of the mesencephalic periaqueductal gray matter of the rat. Brain Research 1994;647:220-30. (Pubitemid 24176084)
92. Nakamura M, Jang IS. Presynaptic nicotinic acetylcholine receptors enhance GABAergic synaptic transmission in rat periaqueductal gray neurons. European Journal of Pharmacology 2010;640:178-84.
93. Ishii K, Wong JK, Sumikawa K. Comparison of a2 nicotinic acetylcholine receptor subunit mRNA expression in the central nervous system of rats and mice. Journal of Comparative Neurology 2005;493:241-60. (Pubitemid 41677479)